What is Amerstem?
Amerstem is at the forefront of sustainable biotechnology, specializing in the vertical farming of plant-derived saponins. The company's core innovation lies in developing saponin immunoadjuvants, such as QS-21, which are critical components for vaccines, personal care items, and agricultural applications. By employing state-of-the-art vertical farming techniques, Amerstem offers an eco-friendly alternative to traditional methods that often rely on the harvesting of Quillaja saponaria trees. This approach not only ensures a consistent and sustainable supply of saponins but also aligns with growing market demands for green biotechnology solutions.
How much funding has Amerstem raised?
Amerstem has raised a total of $459K across 2 funding rounds:
Debt
$150K
Debt
$309K
Debt (2020): $150K with participation from PPP
Debt (2021): $309K led by PPP
What's next for Amerstem?
With substantial late-stage funding, Amerstem is poised for significant expansion and market penetration. The recent strategic investment will likely fuel the scaling of its innovative vertical farming operations and accelerate the commercialization of its saponin-based products, particularly in the high-demand vaccine adjuvant and personal care markets. This capital infusion is expected to bolster research and development efforts, further solidifying Amerstem's position as a leader in sustainable green biotechnology and a key player in the global supply chain for essential saponin compounds.
See full Amerstem company page
